Juan Ibarra Rovira, Selvi Thirumurthi, Melissa Taggart, Bulent Yilmaz, Heather Lin, Linda Lee Zhong, Chinenye Lynette Ejezie, MPH, Fechukwu O. Akhmedzhanov, Abdulrazzak Zarifa, Cheuk Hong Leung, David S. Hong, Raghunandan Vikram

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes

Leah Wells, Michael Cerniglia, Sarah Hall, Audrey C. Jost, Gregory Britt

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

Kyaw Z. Thein, Siqing Fu, Filip Janku, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Daniel D. Karp, Jatin Shah, Denái R. Milton, Jing Gong, Selma Sulovic, Lacey McQuinn, Bettzy A. Stephen, Rivka R. Colen, Brett W. Carter, Funda Meric-Bernstam, Aung Naing

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

Timothy P. DiPeri, Mehmet Demirhan, Daniel D. Karp, Siqing Fu, David S. Hong, Vivek Subbiah, Joann Lim, Leomar Y. Ballester, Jean H. Tayar, Maria E. Suarez-Almazor, Milind Javle, Funda Meric-Bernstam

Audiovestibular Toxicity Secondary to Immunotherapy: Case Series and Literature Review

Joshua C. Page, Paul W. Gidley, Marc-Elie Nader

Issues

EDITORIAL

Return of Results to Patients: A Gesture of Respect and Responsibility

RESEARCH ARTICLE

Audiovestibular Toxicity Secondary to Immunotherapy: Case Series and Literature Review

BRIEF REPORTS

Prognostic Impact of Cytotoxic CD4 T Cells in Tumor Immune Microenvironment of Patients with Breast Cancer

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study

REVIEW ARTICLE

The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review

CASE REPORT

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

CORRIGENDUM

Correction Notice for “Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting” by Dvir et al

Cover Image

Get Email Alerts

This Feature Is Available To Subscribers Only